Thursday, 15 October 2026European Markets

SANDNES SPAREBANK And CAMBODGE NOM. Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - sandnes sparebank (sadg.ol) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
sandnes sparebank (sadg.ol) kr86.40 7.27% 7.96%
cambodge nom. (cbdg.pa) €6450.00 3.1% 0.52%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sandnes sparebank (sadg.ol)

7.27% forward dividend yield and 7.96% return on equity

sandnes sparebank, an independent savings bank, provides a range of banking and investment products to retail and corporate customers in norway. it operates through three segments: retail market, corporate market, and real estate. the company offers fixed rate deposits, deposit accounts, bsu, and tax withholding and other accounts; child, death, income, critical illness, disability, car, home, cabin, contents, ung, and other insurance products; and pension solutions. it also provides bank guarantee, overdrafts, leasing, construction and business loans, factoring and invoice sales; fixed interest, mortgage, car, and other vehicle loans, as well as small loans and refinancing, and green loans; bank and credit cards; various loans and guarantees; and mobile and internet banking services. in addition, the company offers real estate brokerage and general investment advisory services. sandnes sparebank was founded in 1875 and is headquartered in sandnes, norway.

earnings per share

as for profitability, sandnes sparebank has a trailing twelve months eps of kr9.4.

pe ratio

sandnes sparebank has a trailing twelve months price to earnings ratio of 9.19. meaning, the purchaser of the share is investing kr9.19 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.96%.

more news about sandnes sparebank.

2. cambodge nom. (cbdg.pa)

3.1% forward dividend yield and 0.52% return on equity

compagnie du cambodge, together with its subsidiaries, provides transportation and logistics services in france. it operates a railway concession linking burkina faso with ivory coast. the company was incorporated in 1998 and is headquartered in puteaux, france. compagnie du cambodge is a subsidiary of plantations des terres rouges s.a.

earnings per share

as for profitability, cambodge nom. has a trailing twelve months eps of €36.12.

pe ratio

cambodge nom. has a trailing twelve months price to earnings ratio of 178.57. meaning, the purchaser of the share is investing €178.57 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.52%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on jun 20, 2023, the estimated forward annual dividend rate is 180 and the estimated forward annual dividend yield is 3.1%.

more news about cambodge nom..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com